Search in the Abstract Database

Search Abstracts 2016

* = Presenting author

P694 Nationwide prevalence of inflammatory bowel diseases in Hungary: a population-based study based on the National Health Insurance Fund database

Z. Kurti*1, L. Gonczi1, P. A. Golovics1, B. Lovasz1, P. Fadgyas-Freyler2, J. Gimesi-Orszagh2, G. B. Korponai2, Z. Vegh1, P. Lakatos1

1Semmelweis University, First Department of Medicine, Budapest, Hungary, 2National Health Insurance Fund (OEP), Strategic Analysis Department, Budapest, Hungary

Background

Regional studies on inflammatory bowel disease (IBD) suggest an increasing prevalence over time, but no nationwide estimate has been published so far. To estimate the IBD prevalence in 2013 in Hungary overall, by disease, and in specific patient segments.

Methods

Patients were identified according to international classification codes for ulcerative colitis (UC) and Crohn’s disease (CD) in in-patient care, day surgery, non-primary outpatient care and drug prescription databases (2011–2013) of the National Health Insurance Fund (OEP), the only nationwide state-owned health insurance provider in Hungary.

Results

Requiring at least one diagnoses of IBD in non-primary care, a total of 55 039 individuals (men: 44.6%) with physician-diagnosed IBD were alive in Hungary in 2013, corresponding to a prevalence of 0.55% (95% CI, 0.55–0.56).

Figure 1. Prevalence of IBD in the different regions of Hungary.

The prevalence of CD 0.20% (95% CI, 0.19–0.20), and UC was 0.34% (95% CI, 0.33–0.34). The prevalence both in men and women was highest in the 20–39 year-olds in CD, whereas it increased with age in UC, and peaked at ages 50–59 years. Prevalence of actively treated disease (defined as 2 or more IBD-related visits, and at least yearly one dispensed prescription of IBD-related drugs in 2011–2013) was 0.31% (95% CI, 0.31–0.32), 0.13% (95% CI, 0.27–0.28) in CD and 0.18% (95% CI, 0.17–0.18) in UC.

Conclusion

The Hungarian IBD prevalence based on nationwide database of the National Health Insurance Fund was higher compared with previous estimates based on the Veszprem IBD cohort. Prevalence estimates were affected by case definition ranging from 0.31% to 0.55%.